Report cover image

Cutaneous Lupus Erythematosus Market by Clinical Presentation (Acute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus), Drug Class (Antimalarial Drugs, Corticosteroids, Immunosuppressants), Route

Publisher 360iResearch
Published Apr 17, 2024
Length 193 Pages
SKU # IRE18707482

Description

Cutaneous Lupus Erythematosus Market by Clinical Presentation (Acute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus), Drug Class (Antimalarial Drugs, Corticosteroids, Immunosuppressants), Route of Administration, End-Users, Distribution Channel - Global Forecast 2024-2030


The Cutaneous Lupus Erythematosus Market size was estimated at USD 2.07 billion in 2023 and expected to reach USD 2.26 billion in 2024, at a CAGR 9.72% to reach USD 3.96 billion by 2030.

Cutaneous lupus erythematosus (CLE) is a kind of lupus that primarily affects the skin. It is an autoimmune condition, which means that the immune system of the body mistakenly attacks healthy tissue. In the case of CLE, this immune response leads to inflammation and harm to the skin. There are several types of CLE, including acute, subacute, and chronic forms, each presenting with distinct skin lesions and varying degrees of severity. Common symptoms include rashes, particularly on areas of the skin exposed to sunlight, and disc-shaped lesions that might scar. The condition occurs in isolation or as part of systemic lupus erythematosus (SLE), a severe form of lupus affecting multiple organs. Management of CLE involves protective measures against sun exposure, topical treatments, and, in some cases, systemic medications to control the immune response. The growth of the cutaneous lupus erythematosus market is driven by the widening prevalence of lupus and the heightened awareness amongst patients and healthcare providers. The growing innovative treatment methodologies and the development of targeted therapies. However, the expenses associated with biologics and advanced medications for cutaneous lupus erythematosus treatment hinder their adoption. Biotechnology and pharmaceutical research advances offer opportunities for the cutaneous lupus erythematosus market expansion.

Please Note: PDF & Excel + Online Access - 1 Year

Table of Contents

193 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cutaneous lupus erythematosus worldwide
5.1.1.2. Supportive government initiatives and funding for creating awareness among patients
5.1.2. Restraints
5.1.2.1. Expenses associated with biologics and advanced medications for cutaneous lupus erythematosus treatment
5.1.3. Opportunities
5.1.3.1. Emerging regenerative medicine and advances in skin repair
5.1.3.2. Personalized medicine for cutaneous lupus erythematosus treatment
5.1.4. Challenges
5.1.4.1. Limited access to rheumatologists and to newer drugs in certain areas
5.2. Market Segmentation Analysis
5.2.1. Clinical Presentation: Rising adoption of Acute cutaneous lupus erythematosus (ACLE)
5.2.2. End-Users: Widening adoption in the specialty clinics owing to the need for specialized care in managing the complex autoimmune condition
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Cutaneous Lupus Erythematosus Market, by Clinical Presentation
6.1. Introduction
6.2. Acute Cutaneous Lupus Erythematosus
6.3. Chronic Cutaneous Lupus Erythematosus
6.4. Subacute Cutaneous Lupus Erythematosus
7. Cutaneous Lupus Erythematosus Market, by Drug Class
7.1. Introduction
7.2. Antimalarial Drugs
7.3. Corticosteroids
7.4. Immunosuppressants
7.5. Retinoids
8. Cutaneous Lupus Erythematosus Market, by Route of Administration
8.1. Introduction
8.2. Injections
8.3. Oral
8.4. Topical
9. Cutaneous Lupus Erythematosus Market, by End-Users
9.1. Introduction
9.2. Hospitals
9.3. Specialty Clinics
10. Cutaneous Lupus Erythematosus Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Americas Cutaneous Lupus Erythematosus Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Cutaneous Lupus Erythematosus Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Cutaneous Lupus Erythematosus Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. AbbVie and Lupus Therapeutics Partnered for Sle Trial Recruitment
14.3.2. Lupus Landmark Study Launched to Accelerate The Development of Personalized Treatments for Lupus Patients
14.3.3. FDA Launched Lupus Treatment Consortium In Partnership With The Lupus Research Alliance
14.4. Strategy Analysis & Recommendation
15. Competitive Portfolio
15.1. Key Company Profiles
15.2. Key Product Portfolio
FIGURE 1. CUTANEOUS LUPUS ERYTHEMATOSUS MARKET RESEARCH PROCESS
FIGURE 2. CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CUTANEOUS LUPUS ERYTHEMATOSUS MARKET DYNAMICS
FIGURE 7. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY CLINICAL PRESENTATION, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY CLINICAL PRESENTATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 14. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 16. GLOBAL CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. CUTANEOUS LUPUS ERYTHEMATOSUS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. CUTANEOUS LUPUS ERYTHEMATOSUS MARKET, FPNV POSITIONING MATRIX, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us